Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
This study is a visual assessment of diagnostic PET/CT images obtained after a single intravenous injection of BAY85-8050 in patients with cancer
Neoplasm
DRUG: F-18 (BAY85-8050)|DRUG: F-18 (BAY85-8050)
Visual assessment of lesions, Within up to 2 hours after treatment
Quantitative analysis of BAY 85-8050 uptake into lesions (Standardized Uptake Values, SUVs), Within up to 2 hours after treatment|Serum chemistry:Glutamate pyruvate transaminase (GPT/ALAT), gamma-glutamyl transferase (gamma-GT), glutamate-oxaloacetate transaminase (GOT), alkaline phosphatase, total bilirubin, creatinine, total protein, At least 2 times within 8 days after treatment|Electrocardiogram (ECG), at least 2 times within 8 days after treatment|Vital signs: Heart rate, blood pressure, at least 2 times within 8 days after treatment|Adverse events collection, continuously for at least 8 days after treatment
This study is a visual assessment of diagnostic PET/CT images obtained after a single intravenous injection of BAY85-8050 in patients with cancer